WILMINGTON, Del. - Directors are selling Cadence Pharmaceuticals too cheaply through an unfair process to Mallinckrodt, for $14 per share or $1.3 billion, a class action claims in Chancery Court.
Categories / Uncategorized
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.
Additional Reads
-
Federal judge rules against Texas in border barrier lawsuit against DHS November 30, 2023
-
-
FTC vs Facebook November 27, 2023 -
